Abstract: Cycloheximide (CHX) is a naturally occurring glutarimide-containing polyketide first isolated from Streptomyces griseus. Widely recognized as a potent eukaryotic translation elongation inhibitor, CHX has become an indispensable tool in molecular biology, particularly in the fields of ribosome profiling and translation dynamics. By targeting the 60S ribosomal subunit and preventing tRNA from exiting the E-site, CHX effectively halts protein synthesis. Beyond its utility as a research reagent, CHX exhibits significant antifungal, antiviral, and anti-leukemic activities. However, its severe toxicity has historically precluded its clinical application in humans. Recent advances in high-resolution cryo-electron microscopy (cryo-EM) have elucidated the precise binding interactions of CHX within the human 80S ribosome, revitalizing interest in the compound. This structural insight has paved the way for rational, structure-guided drug design, leading to the synthesis of novel CHX derivatives with vastly improved anti-leukemic efficacy and the potential for a viable therapeutic window.
1. Introduction
Cycloheximide (CHX), originally referred to as actidione, was the first discovered glutarimide-containing polyketide (GP), isolated from the bacterium Streptomyces griseus in 1947 [2]. Structurally, CHX is characterized by a bipartate framework consisting of a six-membered glutarimide ring (2,6-piperidinedione) and a polyketide side chain featuring a distinctive 3,5-dimethyl-2-oxocyclohexyl group [2]. The molecule possesses four chiral centers, the stereoconfiguration of which is critical to its biological function [1][2]. CHX is a highly potent cell toxin in eukaryotes and has long been utilized as a fundamental reagent in cellular and molecular biology to study the starting positions of transcription and to arrest protein synthesis [1][2].
2. Pharmacological Activity
CHX and its analogues exhibit a diverse array of biological activities. It displays strong antifungal properties, particularly against plant fungi [2]. Additionally, CHX demonstrates potent antiviral activity against various RNA and DNA viruses, including HIV-1, influenza virus, and Herpes Simplex Virus (HSV) [2]. In the context of oncology, CHX has shown preferential anti-leukemic activity, exhibiting higher toxicity in leukemic cells compared to normal cells [1]. Beyond direct therapeutic applications, CHX has been derivatized into fluorescent probes for the imaging of protein synthesis and has been evaluated as an inhibitor of the FKBP12 protein [1].
3. Molecular Mechanism of Action
The primary mechanism of action of CHX involves the inhibition of protein synthesis by interfering with translocation during translation elongation in eukaryotes, while notably having no effect on E. coli (prokaryotic) protein synthesis [1]. CHX targets the 60S subunit of eukaryotic ribosomes, specifically preventing the tRNA from leaving the ribosomal E-site [2]. High-resolution (3.6 Å) cryo-EM structures of the human cytosolic 80S ribosome in complex with CHX have visualized the compound bound within its specific ribosomal pocket [1].
In the specialized field of ribosome profiling and translation dynamics, CHX is frequently used to stall translation elongation. For instance, CHX treatment prevents the formation of stress granules (SGs) by arresting ribosomes on mRNAs [3]. Interestingly, recent studies on "assemblysomes"—intracellular condensates composed of translationally paused ribosome-nascent chain complexes (RNCs) involved in co-translational assembly and stress responses—reveal that these structures are resistant to CHX. Because translation is already stalled within assemblysomes, the addition of CHX has no further effect on them, distinguishing them from other cellular granules [3].
4. Structure-Activity Relationship (SAR)
Extensive SAR studies have demonstrated that most molecular features of CHX are essential for maintaining its biological activity. The chirality of the molecule is absolutely crucial; modifications to its chiral centers result in a significant loss of activity against protein translation [1]. For antiviral efficacy, the 6-OH and 8-C=O groups have been identified as the primary active moieties [2].
Recent structure-guided rational design has explored alterations to the cyclohexanone moiety. Replacing a methyl group with a butyl chain in this region did not notably decrease activity. However, incorporating electrophilic groups, such as a benzyl ester, improved protein synthesis inhibition by an order of magnitude, likely by enabling interactions with nearby lysine residues [1]. Cryo-EM insights suggest that the 3,5-dimethyl-2-oxocyclohexyl moiety could be extended towards the E-site tRNA CCA end binding-site (inserting between G4370 and G4371). Furthermore, the spatial gap between CHX and the eukaryote-specific ribosomal protein eL42 could be filled by derivatives designed to interact with residues Lys53, Pro54, or Phe56 [1].
5. Current Limitations
The primary limitation of CHX is its severe toxicity, which is too high for direct therapeutic application in humans [1]. Historically, scientific and clinical interest in CHX declined because early synthetic analogues failed to show any meaningful improvement in either bioactivity or toxicity profiles [1]. Even with recent rational design efforts, some newly synthesized CHX analogues that demonstrated enhanced inhibition of protein translation in vitro did not translate into better anti-cancer activity compared to the parental CHX compound [1].
6. Future Perspectives
The advent of high-resolution cryo-EM has revolutionized the potential for structure-guided drug design targeting the human 80S ribosome. By visualizing the exact binding interactions of CHX, medicinal chemists can now rationally manipulate the compound to enhance specificity and reduce toxicity [1]. In an ongoing project leveraging these structural insights, approximately 70 different CHX derivatives have been synthesized. Among these, five novel molecules have demonstrated a 50- to 100-fold improvement in anti-leukemic activity compared to parental CHX, alongside a higher inhibitory effect on the ribosome. These promising derivatives are currently undergoing rigorous in vitro and in vivo characterization to evaluate their toxicity and establish potential therapeutic windows [1]. Furthermore, CHX will continue to serve as an essential chemical probe in ribosome profiling to unravel complex translation dynamics, such as the formation and function of assemblysomes during cellular stress [3].
